(ARDT) Ardent Health Partners - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 1.320m USD | Total Return: -37.5% in 12m
Avg Turnover: 3.96M
Qual. Beats: 0
Rev. Trend: 98.9%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Ardent Health Partners, Inc. (NYSE: ARDT) operates a diversified network of acute care hospitals and ambulatory facilities across several U.S. markets. The company provides a broad spectrum of medical services ranging from general internal medicine to specialized oncology, neurology, and emergency care. Its delivery model integrates inpatient stays with outpatient services, including urgent care centers, diagnostic imaging, and ambulatory surgery centers.
The health care facilities sector is characterized by a shift toward value-based care, where providers are increasingly incentivized to manage patient outcomes across both clinical and telehealth settings. As a subsidiary of EGI-AM Investments, Ardent utilizes a hub-and-spoke business model designed to capture patient volume through local primary care clinics and funnel complex cases to its larger surgical and rehabilitation hospitals.
Investors may find additional data points on ValueRay useful for evaluating the companys long-term valuation metrics. Based in Brentwood, Tennessee, Ardent Health has expanded its infrastructure since its founding in 2001 to include a comprehensive suite of diagnostic and specialty care assets.
- Expansion of ambulatory care footprint drives higher margin outpatient revenue growth
- Strategic joint ventures with local health systems improve regional market share
- Medicare and Medicaid reimbursement rate shifts impact net patient service revenue
- Labor cost inflation for nursing and clinical staff pressures operating margins
- Capital expenditure for facility modernization influences long term free cash flow targets
| Net Income: 134.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.66 > 1.0 |
| NWC/Revenue: 16.62% < 20% (prev 15.46%; Δ 1.17% < -1%) |
| CFO/TA 0.08 > 3% & CFO 430.9m > Net Income 134.3m |
| Net Debt (603.3m) to EBITDA (501.3m): 1.20 < 3 |
| Current Ratio: 2.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (141.8m) vs 12m ago 0.76% < -2% |
| Gross Margin: 49.72% > 18% (prev 0.76%; Δ 4.90k% > 0.5%) |
| Asset Turnover: 126.5% > 50% (prev 122.7%; Δ 3.84% > 0%) |
| Interest Coverage Ratio: 6.55 > 6 (EBITDA TTM 501.3m / Interest Expense TTM 51.8m) |
| A: 0.20 (Total Current Assets 2.02b - Total Current Liabilities 951.5m) / Total Assets 5.25b |
| B: 0.10 (Retained Earnings 541.5m / Total Assets 5.25b) |
| C: 0.07 (EBIT TTM 338.8m / Avg Total Assets 5.08b) |
| D: 0.15 (Book Value of Equity 540.4m / Total Liabilities 3.52b) |
| Altman-Z'' = 2.28 = BBB |
| DSRI: 0.83 (Receivables 686.0m/776.5m, Revenue 6.43b/6.02b) |
| GMI: 1.54 (GM 49.72% / 76.36%) |
| AQI: 0.94 (AQ_t 0.21 / AQ_t-1 0.22) |
| SGI: 1.07 (Revenue 6.43b / 6.02b) |
| TATA: -0.06 (NI 134.3m - CFO 430.9m) / TA 5.25b) |
| Beneish M = -2.73 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 9.29 with a total of 221,281 shares traded.
Over the past week, the price has changed by -8.38%,
over one month by -7.47%,
over three months by -2.00% and
over the past year by -37.53%.
Ardent Health Partners has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy ARDT.
- StrongBuy: 7
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.5 | 34.6% |
P/E Trailing = 9.7979
P/E Forward = 8.4531
P/S = 0.2054
P/B = 0.9876
Revenue TTM = 6.43b USD
EBIT TTM = 338.8m USD
EBITDA TTM = 501.3m USD
Long Term Debt = 1.07b USD (from longTermDebt, last quarter)
Short Term Debt = 37.6m USD (from shortTermDebt, last quarter)
Debt = 1.21b USD (from shortLongTermDebtTotal, last quarter) (leases 1.18b already included)
Net Debt = 603.3m USD (calculated: Debt 1.21b - CCE 609.7m)
Enterprise Value = 1.92b USD (1.32b + Debt 1.21b - CCE 609.7m)
Interest Coverage Ratio = 6.55 (Ebit TTM 338.8m / Interest Expense TTM 51.8m)
EV/FCF = 9.00x (Enterprise Value 1.92b / FCF TTM 213.8m)
FCF Yield = 11.12% (FCF TTM 213.8m / Enterprise Value 1.92b)
FCF Margin = 3.33% (FCF TTM 213.8m / Revenue TTM 6.43b)
Net Margin = 2.09% (Net Income TTM 134.3m / Revenue TTM 6.43b)
Gross Margin = 49.72% ((Revenue TTM 6.43b - Cost of Revenue TTM 3.23b) / Revenue TTM)
Gross Margin QoQ = 15.36% (prev 42.13%)
Tobins Q-Ratio = 0.37 (Enterprise Value 1.92b / Total Assets 5.25b)
Interest Expense / Debt = 4.27% (Interest Expense 51.8m / Debt 1.21b)
Taxrate = 21.59% (16.1m / 74.6m)
NOPAT = 265.7m (EBIT 338.8m * (1 - 21.59%))
Current Ratio = 2.12 (Total Current Assets 2.02b / Total Current Liabilities 951.5m)
Debt / Equity = 0.70 (Debt 1.21b / totalStockholderEquity, last quarter 1.73b)
Debt / EBITDA = 1.20 (Net Debt 603.3m / EBITDA 501.3m)
Debt / FCF = 2.82 (Net Debt 603.3m / FCF TTM 213.8m)
Total Stockholder Equity = 1.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.64% (Net Income 134.3m / Total Assets 5.25b)
RoE = 9.08% (Net Income TTM 134.3m / Total Stockholder Equity 1.48b)
RoCE = 13.28% (EBIT 338.8m / Capital Employed (Equity 1.48b + L.T.Debt 1.07b))
RoIC = 6.13% (NOPAT 265.7m / Invested Capital 4.34b)
WACC = 6.80% (E(1.32b)/V(2.53b) * Re(9.97%) + D(1.21b)/V(2.53b) * Rd(4.27%) * (1-Tc(0.22)))
Discount Rate = 9.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -2.22 | Cagr: -0.11%
[DCF] Terminal Value 77.97% ; FCFF base≈175.6m ; Y1≈201.3m ; Y5≈296.3m
[DCF] Fair Price = 26.90 (EV 4.46b - Net Debt 603.3m = Equity 3.86b / Shares 143.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.43 | # QB: 0
Revenue Correlation: 98.95 | Revenue CAGR: 8.13% | SUE: 0.36 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.26 | Chg30d=-27.97% | Revisions=-43% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.25 | Chg30d=+4.17% | Revisions=-14% | Analysts=4
EPS current Year (2026-12-31): EPS=1.25 | Chg30d=+10.86% | Revisions=+43% | GrowthEPS=-19.1% | GrowthRev=+3.7%
EPS next Year (2027-12-31): EPS=1.32 | Chg30d=+12.82% | Revisions=+43% | GrowthEPS=+5.6% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: -43%